Major interaction on record — check this product against your medications before combining. Based on 2 of 3 ingredients. Check your meds →
Dietary supplement

CholestePure Plus Ingredients & Drug Interactions

by Pure Encapsulations

Capsule Category: Other Combinations
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

CholestePure Plus is a dietary supplement by Pure Encapsulations with 3 active ingredients. Its ingredients are commonly taken for high cholesterol, heart and metabolic health, anxiety and stress (aromatherapy).Based on those ingredients, 1,269 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Berbevis, Bergavit 40. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of CholestePure Plus by Pure Encapsulations

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 3 of its 3 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

CholestePure Plus contains three active ingredients. Bergamot (as Bergavit 40) is a citrus fruit extract studied for cholesterol support.

Berberine (as Bervis) is a plant alkaloid also researched for cholesterol and blood sugar. Phytosterols are plant compounds with a role in cholesterol management, though we hold no interaction data for them.

The product also includes several inactive ingredients—pea protein, sunflower lecithin, grape seed extract, cellulose, fiber, and other excipients that serve as fillers and binders.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Cholesterol and heart health support.
  • We looked for evidence on: Coronary heart disease (CHD), Hyperlipidemia, Hypertension, Metabolic syndrome, Lipid management, Cardiovascular function.
  • The strongest evidence on file: Bergamot is rated "Possibly Effective" for Hyperlipidemia (Natural Medicines).
  • Also on file: Berberine is rated "Possibly Effective" for Hyperlipidemia, Hypertension.
  • Also on file: Bergamot is rated "Insufficient Reliable Evidence To Rate" for Metabolic syndrome.

For high cholesterol (hyperlipidemia), both bergamot and berberine are rated possibly effective—the evidence suggests they may help, but it isn't airtight. Berberine is also possibly effective for polycystic ovary syndrome (PCOS), blood sugar control (diabetes), high blood pressure (hypertension), and Helicobacter pylori infection.

The evidence for bergamot on mental alertness is rated possibly ineffective, and for fatty liver disease and autism spectrum disorder, the data is too sparse to rate either way.

The evidence, ingredient by ingredient Bergamot Berberine

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Bergamot extract taken by mouth is generally well tolerated short-term; the main risk is the essential oil, which can be toxic if swallowed and cause sun-related skin reactions, especially in fair-skinned people. Berberine is generally well tolerated short-term but commonly causes digestive upset—abdominal pain, bloating, constipation, diarrhea, gas, and nausea—and may also cause dizziness, drowsiness, fatigue, or headache.

Both ingredients are contraindicated in pregnancy and breastfeeding: bergamot is possibly unsafe, and berberine is likely unsafe for both, as it can cross the placenta and enter breast milk.

Side effects, ingredient by ingredient Bergamot Berberine

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Bergamot, Berberine.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,270 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking this product, check with your pharmacist if you take cyclosporine (a Major interaction with berberine). Also double-check if you're on blood thinners or antiplatelet drugs, blood pressure medications, diabetes drugs, sedatives or other CNS depressants, photosensitizing medications, or any drug metabolized by the liver's P450 enzyme system.

These Moderate interactions need personalized review.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

CholestePure Plus may help with cholesterol and blood sugar, but it interacts with many medications—especially blood thinners, blood pressure drugs, diabetes medications, and sedatives. If you take cyclosporine, do not start this product without checking with your doctor or pharmacist first.

Avoid it entirely if you're pregnant or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Dec 14, 2023.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about CholestePure Plus, straight from the product label.

Brand Pure Encapsulations
Barcode (UPC) 766298025537
Net contents 120 Capsule(s)
Market status On market
Date entered into DSLD Dec 14, 2023
DSLD ID 299745
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Women (not pregnant or lactating), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for CholestePure Plus by Pure Encapsulations, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
Servings per container
60
UPC/BARCODE
766298025537
IngredientAmount% DV
Bergavit 40160 mg--
Phytosterols500 mg--
Berbevis275 mg--

Other ingredients: Pea Protein Isolate, Sunflower Lecithin, Grape Seed Extract, Cellulose, Silicon Dioxide, Cellulose, Water, hypoallergenic Plant Fiber, Ascorbyl Palmitate

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Storage

Store in a cool, dry place.

Suggested/Recommended/Usage/Directions

Recommendations: As a dietary supplement, take 2 capsules, 1-2 times daily, with meals.

Precautions

Warning: Not to be taken by pregnant or lactating women. If you have any health condition or are taking any medication, consult your health professional before use.

Keep out of the reach of children.

Use only if safety seal is intact.

General Statements

Contents may not fill package in order to accommodate required labeling. Please rely on stated quantity. Scan to learn about our hypoallergenic supplements

Seals/Symbols

GFCO.org (Gluten-Free Certification Organization)

Formulation

Certified Gluten-Free by the Gluten-Free Certified Organization www.gluten.org

With enhanced absorption Phytosome technology; Supports healthy lipid metabolism and cardiometabolic health Gluten-Free, Soy-free, Non-GMO & Hypoallergenic

Gluten-Free, Soy-free, Non-GMO & Hypoallergenic

FDA Statement of Identity

Dietary Supplement

Brand IP Statement(s)

PhytoPin is a registered trademark DRT and licensed to Pure Encapsulations. Berbevis and Phytosome are trademarks of Indena S.p.A., Italy. Bergavit 40 is a registered trademark of Bionap S.r.l.

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

See for yourself

CholestePure Plus by Pure Encapsulations label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in CholestePure Plus by Pure Encapsulations

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Bergavit 40

Interacts with
410 drugs
160 mg per serving Form: Bergamot Fruit Extract

Bergamot is a Mediterranean citrus fruit, and its standardized extract is most often used to support cholesterol and heart health, with some early but...

Bergavit 40 monograph & interactions

Phytosterols

500 mg per serving Form: PhytoPin

Berbevis

Interacts with
1,160 drugs
275 mg per serving Form: Berberine Phytosome

Berberine is a yellow plant compound that has shown promise for lowering blood sugar and cholesterol in some studies, but the quality of research vari...

Berbevis monograph & interactions

Other (inactive) ingredients: Pea Protein Isolate, Sunflower Lecithin, Grape Seed Extract, Cellulose, Silicon Dioxide, Cellulose, Water, Hypoallergenic Plant Fiber, Ascorbyl Palmitate. These complete the product’s ingredient list but are not active constituents.

Interaction report

CholestePure Plus by Pure Encapsulations Drug Interactions

Want to check YOUR meds against CholestePure Plus?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,269Drugs
1 Major 1,268 Moderate

Ingredients driving the most interactions

Berbevis 1,160

Each ingredient & the kinds of drugs it affects

For each ingredient in CholestePure Plus with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Berbevis15 drug types · 1,160 drugs

Cyclosporine (Neoral, Sandimmune)

Berberine can increase serum levels of cyclosporine.
Berberine can reduce metabolism and increase serum levels of cyclosporine. Berberine might inhibit cytochrome P450 3A4 (CYP3A4), which metabolizes cyclosporine.

Likelihood Probable Evidence A
Anticoagulant/Antiplatelet Drugs

Theoretically, berberine might increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.
In vitro and in vivo research suggest that berberine can inhibit platelet aggregation. Theoretically, berberine might have additive effects when used with anticoagulant and antiplatelet drugs and increase the risk of bleeding.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, berberine may increase the risk of hypoglycemia when taken with antidiabetes drugs.
Clinical research shows that berberine may lower blood glucose levels. Theoretically, berberine might have additive effects with antidiabetes drugs and increase the risk of hypoglycemia.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, berberine might have additive effects with antihypertensive drugs.
Animal research suggests that berberine can have hypotensive effects. Also, a clinical study suggests that taking berberine in combination with amlodipine can lower systolic and diastolic blood pressure when compared with amlodipine alone.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, berberine might increase the sedative effects of CNS depressants.
Animal research suggests that berberine may have sedative effects. Theoretically, use of berberine along with CNS depressants might produce additive therapeutic and adverse effects.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP2C9.
Preliminary clinical research shows that berberine can inhibit CYP2C9. Theoretically, taking berberine with drugs metabolized by CYP2C9 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence B
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP2D6.
In vitro research and preliminary clinical evidence show that berberine can inhibit CYP2D6. Theoretically, use of berberine with drugs metabolized by CYP2D6 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP3A4.
In vitro research and preliminary clinical research show that berberine moderately inhibits CYP3A4. Theoretically, use of berberine with drugs metabolized by CYP3A4 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence A
Dextromethorphan (Robitussin Dm, Others)

Theoretically, berberine may increase serum levels of dextromethorphan.
Preliminary clinical research shows that berberine can inhibit cytochrome P450 2D6 (CYP2D6) activity and reduce the metabolism of dextromethorphan. This may increase the effects and side effects of dextromethorphan.

Likelihood Possible Evidence B
Losartan (Cozaar)

Berberine might reduce the therapeutic effects of losartan by decreasing its conversion to its active form.
Preliminary clinical research suggests that berberine can inhibit cytochrome P450 2C9 (CYP2C9) activity and reduce metabolism of losartan.

Likelihood Possible Evidence B
Metformin (Glucophage)

Theoretically, berberine might increase the therapeutic and adverse effects of metformin.
In vitro and animal studies show that berberine can increase the systemic exposure and half-life of metformin, potentially increasing metformin's effects and side effects. This interaction seems to be most apparent when berberine is administered 2 hours prior to metformin. Taking berberine and metformin at the same time does not appear to increase systemic exposure to metformin.

Likelihood Possible Evidence D
Midazolam (Versed)

Berberine can reduce metabolism of midazolam, which might increase the risk of severe adverse effects.
Preliminary clinical research shows that berberine can inhibit cytochrome P450 3A4 (CYP3A4) activity and reduce metabolism of midazolam.

Likelihood Possible Evidence B
Pentobarbital (Nembutal)

Berberine might increase the sedative effect of pentobarbital.
Evidence from animal research shows that berberine can prolong pentobarbital-induced sleeping time. Theoretically, combining berberine and pentobarbital might increase the sedative effects of pentobarbital.

Likelihood Possible Evidence D
Tacrolimus (Prograf)

Berberine has been associated with increased blood levels of tacrolimus.
In a 16-year-old patient with idiopathic nephrotic syndrome who was being treated with tacrolimus 6.5 mg twice daily, intake of berberine 200 mg three times daily increased the blood concentration of tacrolimus from 8 to 22 ng/mL. Following a reduction of the tacrolimus dose to 3 mg daily, blood levels of tacrolimus decreased to 12 ng/mL.

Likelihood Possible Evidence D
Acetazolamide

Laboratory studies and initial clinical findings suggest that berberine has the potential to increase acetazolamide concentrations in the body. More research is needed to confirm this interaction.

Likelihood Possible Evidence C

Bergavit 402 drug types · 410 drugs

Antidiabetes Drugs

Theoretically, taking bergamot with antidiabetes drugs might increase the risk of hypoglycemia.
Animal research suggests that bergamot juice has hypoglycemic effects.

Likelihood Possible Evidence D
Photosensitizing Drugs

Theoretically, topical bergamot essential oil might increase the risk of side effects when used along with photosensitizing drugs.
Bergamot contains bergapten, which has photosensitizing effects.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for CholestePure Plus, from the product label.

Pure Encapsulations

See all Pure Encapsulations products
Name
Pure Encapsulations
Street Address
490 Boston Post Road
City
Sudbury
State
MA
Phone Number
1-800-753-2277
Web Address
www.PureEncapsulations.com
Pharmacist Counseling Corner

CholestePure Plus by Pure Encapsulations: Common Questions

Does CholestePure Plus by Pure Encapsulations interact with any medications?
Yes. Based on its ingredients, CholestePure Plus has a known interaction with 1,269 medications, including 1 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
CholestePure Plus contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I'm pregnant or breastfeeding?
No. Both bergamot and berberine are contraindicated in pregnancy and lactation—bergamot is possibly unsafe and berberine is likely unsafe for both, as it can cross into breast milk and has been linked to harm in newborns. Talk with your doctor before considering any supplement.
What digestive side effects might I notice?
Berberine commonly causes abdominal pain, bloating, constipation, diarrhea, gas, and nausea, especially when you first start it. These usually settle down, but if they're severe or don't improve, tell your pharmacist or doctor.
Is this safe to use with sunscreen and time outdoors?
Bergamot can make your skin sensitive to sunlight, especially if you're fair-skinned. If you spend a lot of time in the sun, use broad-spectrum sunscreen and consider whether this product is right for you. Ask your pharmacist if you're concerned.
Will this lower my blood sugar if I take diabetes medication?
Both ingredients may lower blood sugar on their own, so combining them with diabetes drugs could increase the risk of low blood sugar (hypoglycemia). Your doctor or pharmacist may need to monitor your levels or adjust your medication dose.
Can I take this with blood thinners like warfarin?
Berberine may increase bleeding risk if used with blood thinners or antiplatelet drugs. This is a Moderate interaction, so you'll need to talk with your doctor or pharmacist before combining them.
What does this product actually do?
Both bergamot and berberine are possibly effective for high cholesterol, and berberine is also studied for blood sugar, blood pressure, and PCOS. The evidence is promising but not definitive—results vary from person to person.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if CholestePure Plus is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

CholestePure Plus label
Sources

Sources & How We Checked

CholestePure Plus's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 58 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bergamot 17 references
  1. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  2. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  3. Naganuma M, Hirose S, Nakayama Y, et al. A study of the phototoxicity of lemon oil. Arch Dermatol Res 1985;278:31-6. . PubMed
  4. Kaddu, S., Kerl, H., and Wolf, P. Accidental bullous phototoxic reactions to bergamot aromatherapy oil. J.Am.Acad.Dermatol. 2001;45(3):458-461. PubMed
  5. Finsterer, J. Earl Grey tea intoxication. Lancet 4-27-2002;359(9316):1484. PubMed
  6. Gruson, L. M. and Chang, M. W. Berloque dermatitis mimicking child abuse. Arch.Pediatr.Adolesc.Med. 2002;156(11):1091-1093. PubMed
  7. Weisenseel, P. and Woitalla, S. [Toxic mustard plaster dematitis and phototoxic dematitis after application of bergamot oil]. MMW.Fortschr.Med. 12-15-2005;147(51-52):53, 55.
  8. Placzek, M., Fromel, W., Eberlein, B., Gilbertz, K. P., and Przybilla, B. Evaluation of phototoxic properties of fragrances. Acta Derm.Venereol. 2007;87(4):312-316. PubMed
  9. Mollace, V., Sacco, I., Janda, E., Malara, C., Ventrice, D., Colica, C., Visalli, V., Muscoli, S., Ragusa, S., Muscoli, C., Rotiroti, D., and Romeo, F. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. F PubMed
  10. Morliere, P., Huppe, G., Averbeck, D., Young, A. R., Santus, R., and Dubertret, L. In vitro photostability and photosensitizing properties of bergamot oil. Effects of a cinnamate sunscreen. J.Photochem.Photobiol.B 1990;7(2-4):199-208. PubMed
  11. Young, A. R., Walker, S. L., Kinley, J. S., Plastow, S. R., Averbeck, D., Morliere, P., and Dubertret, L. Phototumorigenesis studies of 5-methoxypsoralen in bergamot oil: evaluation and modification of risk of human use in an albino mouse skin model. J.P PubMed
  12. Girard, J., Unkovic, J., Delahayes, J., and Lafille, C. [Phototoxicity of Bergamot oil. Comparison between humans and guinea pigs]. Dermatologica 1979;158(4):229-243.
  13. Zaynoun, S. T., Johnson, B. E., and Frain-Bell, W. A study of oil of bergamot and its importance as a phototoxic agent. II. Factors which affect the phototoxic reaction induced by bergamot oil and psoralen derivatives. Contact Dermatitis 1977;3(5):225-23 PubMed
  14. Zacher, K. D. and Ippen, H. [Contact dermatitis caused by bergamot oil]. Derm.Beruf.Umwelt. 1984;32(3):95-97.
  15. Yasui, Y. and Hirone, T. Action spectrum for bergamot-oil phototoxicity measured by sunburn cell counting. J.Dermatol. 1994;21(5):319-322. PubMed
  16. Zaynoun, S. T., Johnson, B. E., and Frain-Bell, W. A study of oil of bergamot and its importance as a phototoxic agent. I. Characterization and quantification of the photoactive component. Br.J.Dermatol. 1977;96(5):475-482. PubMed
  17. Bruno A, Pandolfo G, Crucitti M, Cedro C, Zoccali RA, Muscatello MRA. Bergamot Polyphenolic Fraction Supplementation Improves Cognitive Functioning in Schizophrenia: Data From an 8-Week, Open-Label Pilot Study. J Clin Psychopharmacol 2017;37(4):468-71. PubMed

See these in context on the Bergamot monograph →

Berberine 41 references
  1. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate 1993;63:201-8. PubMed
  2. Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia 2000;71:25-33.. PubMed
  3. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005;61:567-72. PubMed
  4. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-65. PubMed
  5. Huang XS, Yang GF, Pan YC. Effect of berberin hydrochloride on blood concentration of cyclosporine A in cardiac transplanted patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008;28:702-4.
  6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  7. Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003;31:1391-7. PubMed
  8. Marin-Neto, J. A., Maciel, B. C., Secches, A. L., and Gallo, Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin.Cardiol. 1988;11(4):253-260. PubMed
  9. Choudhry, V. P., Sabir, M., and Bhide, V. N. Berberine in giardiasis. Indian Pediatr. 1972;9(3):143-146.
  10. Shanbhag, S. M., Kulkarni, H. J., and Gaitonde, B. B. Pharmacological actions of berberine on the central nervous system. Jpn.J Pharmacol 1970;20(4):482-487. PubMed
  11. Wu, J. F. and Liu, T. P. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion]. Yao Xue.Xue.Bao. 1995;30(2):98-102.
  12. Peng, W. H., Hsieh, M. T., and Wu, C. R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997;74(3):261-266. DOI
  13. Sharda DC. Berberine in the treatment of diarrhoea of infancy and childhood. J Indian M A 1970;54(1):22-24.
  14. Sabir M and Bhide NK. Study of some pharmacological actions of berberine. Ind J Physiol & Pharmac 1971;15(3):111-132.
  15. Tripathi YB and Shukla SD. Berberis artistata inhibits PAF induced aggregation of rabbit platelets. Phytotherapy Research 1996;10:628-630.
  16. Seery TM and Bieter RN. A contribution to the pharmacology of berberine. J Pharmacol Exp Ther 1940;69:64-67. DOI
  17. Xin, H. W., Wu, X. C., Li, Q., Yu, A. R., Zhong, M. Y., and Liu, Y. Y. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find.Exp.Clin Pharmacol 2006;28(1):25-29.
  18. Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., Ren, G., and Ning, G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol.Metab 2008;93(7):2559-2565. PubMed
  19. Yin, J., Xing, H., and Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57(5):712-717. PubMed
  20. Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., Wang, S. K., Zhou, Z. X., Song, D. Q., Wang, Y. M., Pan, H. N., Kong, W. J., and Jiang, J. D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin re
  21. Guo, Y., Chen, Y., Tan, Z. R., Klaassen, C. D., and Zhou, H. H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68(2):213-217. PubMed
  22. Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., and Guan, Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndro
  23. Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. PubMed
  24. Meng, S., Wang, L. S., Huang, Z. Q., Zhou, Q., Sun, Y. G., Cao, J. T., Li, Y. G., and Wang, C. Q. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp.Pharmacol Physiol 2012;39 PubMed
  25. Hermann, R. and von, Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78(13):1458-1477. PubMed
  26. Chun YT, Yip TT, Lau KL, and et al. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmac 1979;10:177-182. PubMed
  27. Saksena HC, Tomar VN, and Soangra MR. Efficacy of a new salt of Berberine Uni-Berberine in oriental sore. Current Medical Practice 1970;14:247-252.
  28. Abascal K, Yarnell E. Recent clinical advances with berberine. Altern Complement Ther 2010;16(5):281-7. DOI
  29. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 2013;79(6):437-46. PubMed
  30. Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol 2013;69(10):1861-2. PubMed
  31. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81. PubMed
  32. Li G, Zhao M, Qiu F, Sun Y, Zhao L. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. Drug Des Devel Ther. 2018;13:129-139. PubMed
  33. Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34. PubMed
  34. Xu L, Zhang Y, Xue X, et al. A phase I trial of berberine in Chinese with ulcerative colitis. Cancer Prev Res (Phila). 2020;13(1):117-26. PubMed
  35. Lyu Y, Zhang Y, Yang M, et al. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota. Life Sci. 2019;235:116818. PubMed
  36. Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267-75. PubMed
  37. Zhang J, Wang Y, Jiang H, et al. Preventive effect of berberine on postoperative atrial fibrillation. Circ Arrhythm Electrophysiol 2022;15(10):e011160. PubMed
  38. Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs 2023;83(5):403-427. PubMed
  39. Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocr Disord 2023;23(1):190. PubMed
  40. Nie Q, Li M, Huang C, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med 2024;22(1):225. PubMed
  41. Koperska A, Moszak M, Seraszek-Jaros A, Bogdanski P, Szulinska M. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled tr

See these in context on the Berberine monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring